SCHEMBL40797

SCHEMBL40797

[CH2]C[Si](c1ccccc1)(c1ccccc1)C(C)(C)C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 2/20 0.32
SLC6A2 P23975 1/20 0.32
ATM Q13315 1/20 0.31
ESR1 P03372 1/20 0.31
ESR2 Q92731 1/20 0.31
CACNA1F O60840 1/20 0.31
CHRM2 P08172 1/20 0.31
CHRM1 P11229 1/20 0.31
ADRA2B P18089 1/20 0.31
CHRM3 P20309 1/20 0.31
ADRA1A P35348 1/20 0.31
HRH1 P35367 1/20 0.31
OPRK1 P41145 1/20 0.31
CACNA1D Q01668 1/20 0.31
SLC6A3 Q01959 1/20 0.31
KCNH2 Q12809 1/20 0.31
CACNA1S Q13698 1/20 0.31
CACNA1C Q13936 1/20 0.31
SCN5A Q14524 1/20 0.31
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28549833 0.98 TAAR1 (0.31) TAAR1SLC6A2ATMESR1ESR2
SCHEMBL14770816 0.79 TP53 (0.35) TAAR1SLC6A2ATMESR1ESR2
SCHEMBL8701181 0.77 CYP2C19 (0.38) TAAR1SLC6A2ESR1ESR2
SCHEMBL2591855 0.77 TAAR1 (0.32) TAAR1SLC6A2ATMESR1ESR2
SCHEMBL2617396 0.77 TAAR1 (0.32) TAAR1SLC6A2ATMESR1ESR2
SCHEMBL22034849 0.77 MAPT (0.35) ATMMAPK1
SCHEMBL28491406 0.76 MAPK1 (0.33) TAAR1SLC6A2ATMESR1ESR2
SCHEMBL8056864 0.74 MAPT (0.33) TAAR1SLC6A2
SCHEMBL11899211 0.74 TAAR1 (0.30) TAAR1SLC6A2
SCHEMBL506540 0.74 NR1H2 (0.33) ESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2668176-B1 A NOVEL PROCESS FOR SYNTHESIS OF POLYPHENOLS SPHAERA PHARMA PTE LTD (SG) 2017-05-17 EP claimed
US-9428482-B2 Process for synthesis of polyphenols SPHAERA PHARMA PTE. LTD. (SG) 2016-08-30 US claimed
CN-103582635-A A novel process for synthesis of polyphenols SPHAERA PHARMA PRIVATE LTD 2014-02-12 CN claimed
US-20140031421-A1 NOVEL PROCESS FOR SYNTHESIS OF POLYPHENOLS SPHAERA PHARMA PTE. LTD. (SG) 2014-01-30 US claimed
US-20240067599-A1 IODOTYROSINE DERIVATIVES AND PROCESS FOR PREPARING IODOTYROSINE DERIVATIVES ABX ADVANCED BIOCHEMICAL COMPOUNDS - BIOMEDIZINISCHE FORSCHUNGSREAGENZIEN GMBH (DE) 2024-02-29 US disclosed
EP-4276092-A1 COMPOUND LIBRARY CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-11-15 EP disclosed
CN-116783160-A Libraries of compounds 中外制药株式会社 2023-09-19 CN disclosed
US-20230101138-A1 POLYMER COMPOUND, METHOD FOR PRODUCING POLYMER COMPOUND, ADHESIVE COMPOSITION, CURED PRODUCT, METHOD FOR PRODUCING ADHESIVE COMPOSITION, AND METHOD FOR ADJUSTING ADHESION FORCE NATIONAL INSTITUTE FOR MATERIALS SCIENCE (JP) 2023-03-30 US disclosed
EP-4101870-A1 POLYMER COMPOUND, METHOD FOR PRODUCING POLYMER COMPOUND, ADHESIVE COMPOSITION, CURED PRODUCT, METHOD FOR PRODUCING ADHESIVE COMPOSITION, AND METHOD FOR ADJUSTING ADHESIVE STRENGTH National Institute for Materials Science (JP) 2022-12-14 EP disclosed
CN-103582635-B Method for synthesizing polyphenol 斯法尔制药私人有限公司 2019-02-19 CN disclosed
EP-2668176-B1 A NOVEL PROCESS FOR SYNTHESIS OF POLYPHENOLS SPHAERA PHARMA PTE LTD (SG) 2017-05-17 EP disclosed
US-9556140-B2 Approach for synthesis of catechins SPHAERA PHARMA PVT. LTD. (IN) 2017-01-31 US disclosed
US-5719275-A REACTING SILYL ENOL ETHER WITH AZETIDINONE DERIVATIVE TO FORM INTERMEDIATE FOR PENICILLIN-TYPE ANTIBIOTIC SANKYO COMPANY, LIMITED (JP) 1998-02-17 US disclosed
US-5681951-A REACTING PENICILLIN DERIVATIVE HAVING SULFINYL OR SULFONYL GROUP IN 2 POSITION WITH SUBSTITUTED MERCAPTAN IN PRESENCE OF SALT OF GROUP IIA OR IIIA ELEMENT SANKYO COMPANY, LIMITED (JP) 1997-10-28 US disclosed
EP-0801071-A1 LEWIS X DERIVATIVE AND PROCESS FOR PRODUCING THE SAME SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1997-10-15 EP disclosed
US-5614624-A THIO SUBSTITUTED, ANTIBIOTICS, CHEMICAL INTERMEDIATES SANKYO COMPANY, LIMITED (JP) 1997-03-25 US disclosed
US-5541317-A PENICILLIN DERIVATIVES, CYCLIZATION OF ESTERS OR THIOESTERS SANKYO COMPANY, LIMITED (JP) 1996-07-30 US disclosed
EP-0714393-A1 THIAZOLES AS ANTIVIRAL PFIZER INC. (US) 1996-06-05 EP disclosed
WO-1995005378-A1 ANTIVIRAL THIAZOLES PFIZER INC. (US) 1995-02-23 WO disclosed
EP-0587436-A1 Process for preparing carbapenem and penem compounds and new compounds involved in that process SANKYO COMPANY LIMITED (JP) 1994-03-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031421-A1 NOVEL PROCESS FOR SYNTHESIS OF POLYPHENOLS COMT, NQO1, SPR TAAR1 4592/4885SLC6A2 4467/4885ATM 3606/4885
US-20240067599-A1 IODOTYROSINE DERIVATIVES AND PROCESS FOR PREPARING IODOTYROSINE DERIVATIVES ALK, ALKBH3, INSR TAAR1 22/4885SLC6A2 2493/4885ATM 2463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.